Everything below concerns synaptogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-02-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
=== Availability === Cyproheptadine is available widely throughout the world. This includes in Australia, Canada, Europe, Hong Kong, India, Japan, Mexico, Turkey, the United Kingdom, and the United States, among others.
9 September A study describes how multiple tipping points in the climate system could be triggered if global warming exceeds 1.5 °C. Scientists report a change in gene TKTL1 as a key factor of recent brain evolution and difference of modern humans to (other) apes and Neanderthals, related to neocortex-neurogenesis. Some of the scientists reported a similar ARHGAP11B mutation in 2016. News outlets report about a study that describes a way by which geothermal power plants could store their energy within their reservoirs for dispatch to (better) help manage intermittency of solar and wind. China reports the discovery of Changesite–(Y), a new mineral from lunar samples containing helium-3, widely seen as a potential fuel for fusion reactors. 12 September – A study investigates funding allocations for public investment in energy research, development and demonstration. It provides insights about potential past impacts of drivers, that may be relevant to adjusting (or facilitating) "investment in clean energy" "to come close to achieving meaningful global decarbonization", suggesting advancement of impactful "coopetition". 13 September A study reports results indicating COVID-19 may significantly increase risk for Alzheimer's disease, similar to prior studies about long-term impacts besides long COVID on cardiovascular outcomes, diabetes, neurologic sequelae, mental health disorders, and general future mortality after COVID-19, including specific types of sequelae less commonly seen in other viral illnesses.
Somatostatin is a G protein-coupled receptor ligand. When the receptors are activated, it causes the cells where the receptors are expressed to decrease hormone secretion. Mainly, as a neuroendocrine inhibitor, it exerts its effects on the gastrointestinal tract, pancreas, hypothalamus, and central nervous system, causing hormone secretions coupled to this pathway to be reduced. It can affect neurotransmission and memory formation within the central nervous system. Within human and animal models, it demonstrated its effects of preventing angiogenesis and reducing healthy and cancer cell proliferation. Within tumors, somatostatin receptors, mostly of the ssrt2 subtype, are expressed in most neuroendocrine tumors, breast tumors, some brain tumors, renal tumors, lymphomas, and prostate tumors.
=== July === 1 July Ofgem lowers the energy price cap, saving the average household £122 a year on gas and electric. Passenger and crew of British Airways Flight 149, which was seized by Iraqi authorities when it landed at Kuwait International Airport in August 1990 at the start of the Gulf crisis, are to sue British Airways and the UK government for "deliberately endangering" them after they were held hostage by Iraq. For the second time in three months, military horses break free and run loose through central London. Euro 2024: UEFA investigate Jude Bellingham for a gesture he made following his late equaliser against Slovakia in England's victory in the last-16 tie. Bellingham says it was an inside joke directed at close friends. 2 July Three-time tennis champion Andy Murray, 37, withdraws from the Wimbledon singles, following recent surgery on his back. He will attempt to compete in the doubles, which are likely to mark his final appearance in the tournament prior to retiring later in the year. Following her conviction in August 2023, former neonatal nurse Lucy Letby is found guilty in a separate retrial of attempting to murder a premature child, referred to in court as Baby K. St James's University Hospital nursing assistant Mohammad Farooq is convicted at Sheffield Crown Court of crimes relating to plotting lone wolf attacks on RAF Menwith Hill in North Yorkshire and his Leeds workplace. Data obtained by BBC News shows that 1.8 million people owe at least £50,000 in student debt.
Sources: en.wikipedia.org
== History == The prothrombin time was developed by Armand J. Quick and colleagues in 1935, and a second method was published by Paul Owren, also called the "p and p" or "prothrombin and proconvertin" method. It aided in the identification of the anticoagulants dicumarol and warfarin, and was used subsequently as a measure of activity for warfarin when used therapeutically. The INR was invented in the early 1980s by Tom Kirkwood working at the UK National Institute for Biological Standards and Control (and subsequently at the UK National Institute for Medical Research) to provide a consistent way of expressing the prothrombin time ratio, which had previously suffered from a large degree of variation between centres using different reagents. The INR was coupled to Dr Kirkwood's simultaneous invention of the International Sensitivity Index (ISI), which provided the means to calibrate different batches of thromboplastins to an international standard. The INR became widely accepted worldwide, especially after endorsement by the World Health Organization.
The Decline of Intergenerational Coresidence in the United States, 1850 to 2000. American Sociological Review, vol. 72 (2007), pp. 962–989 Patricia Kelly Hall and Steven Ruggles. 'Restless in the Midst of Their Prosperity': New Evidence on the Internal Migration of Americans, 1850–2000. Journal of American History, vol. 91 (2004), pp. 829–846 Ruggles, Steven. The Rise of Divorce and Separation in the United States, 1880–1990. Demography, vol. 34 (1997), pp. 962–989 Ruggles, Steven. The Transformation of American Family Structure. American Historical Review, vol. 99 (1994), pp. 103–128 Ruggles, Steven. The Origins of African-American Family Structure. American Sociological Review, vol. 59 (1994), pp. 136–151 Ruggles, Steven. Migration, Marriage, and Mortality: Correcting Sources of Bias in English Family Reconstitutions. Population Studies, vol. 46 (1992), pp. 507–522 Ruggles, Steven (1987). Prolonged Connections: The Rise of the Extended Family in Nineteenth-Century England and America. Madison: University of Wisconsin Press. pp. xx, 282. ISBN 0-299-11030-3.
==== Sudden infant death syndrome (SIDS) ==== Recent studies have shown that SIDS infants show decreased levels of ChAT in both the hypothalamus and the striatum. SIDS infants also display fewer neurons capable of producing ChAT in the vagus system. These defects in the medulla could lead to an inability to control essential autonomic functions such as the cardiovascular and respiratory systems.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.